Grading the intensity of nondental orofacial pain: identification of cutoff points for mild, moderate, and severe pain

Vlaho Brailo1
Joanna M Zakrzewska2
1Department of Oral Medicine, School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 2Facial Pain Unit, Division of Diagnostic, Surgical and Medical Sciences, Eastman Dental Hospital, UCLH NHS Foundation Trust/University College London, London, UK

Background: When assessing pain in clinical practice, clinicians often label pain as mild, moderate, and severe. However, these categories are not distinctly defined, and are often used arbitrarily. Instruments for pain assessment use more sophisticated scales, such as a 0–10 numerical rating scale, and apart from pain intensity assess pain-related interference and disability. The aim of the study was to identify cutoff points for mild, moderate, and severe nondental orofacial pain using a numerical rating scale, a pain-related interference scale, and a disability measurement.

Materials and methods: A total of 245 patients referred to the Facial Pain Unit in London were included in the study. Intensity and pain-related interference were assessed by the Brief Pain Inventory. Pain-related disability was assessed by the Chronic Graded Pain Scale. Average pain intensity (0–10) was classified into nine schemes with varying cutoff points of mild, moderate, and severe pain. The scheme with the most significant intergroup difference, expressed by multivariate analysis of variance, provided the cutoffs between mild, moderate, and severe pain.

Results: The combination that showed the greatest intergroup differences for all patients was scheme 47 (mild 1–4, moderate 5–7, severe 8–10). The same combination provided the greatest intergroup differences in subgroups of patients with temporomandibular disorder and chronic idiopathic facial pain, respectively. Among the trigeminal neuralgia patients alone, the combination with the highest intergroup differences was scheme 48 (mild 1–4, moderate 5–8, severe 9–10).

Conclusion: The cutoff points established in this study can discriminate in pain intensity categories reasonably well, and showed a significant difference in most of the outcome measures used.

Keywords: chronic orofacial pain, cutoff point, trigeminal neuralgia, temporomandibular disorder

Introduction

After the correct diagnosis has been established, a vital step for effective treatment of chronic pain is assessment of its intensity and impact. Clinicians most often use categories like mild, moderate, and severe. The categories are not distinctly defined, and are often used arbitrarily. More sophisticated tools like the Brief Pain Inventory (BPI) or the Chronic Graded Pain Scale1,2 most often use a 0–10 numeric rating scale (NRS). Apart from pain intensity, these instruments assess the degree of pain-related functional interference and its impact on quality of life. In spite of the availability of these instruments, many clinicians prefer the use of the mild, moderate, and severe categories.

The question, therefore, arises if it is possible to define more precisely categories like mild, moderate, and severe using these instruments. An NRS cannot just be divided...
into three equal parts, because the relationship between pain intensity and functional interference is not linear. The reduction in the same interval of intensity on different parts of an NRS does not produce similar reduction in functional impairment or patient’s general well-being. The relationship between pain intensity and pain-related interference would thus be more correctly defined by identifying cutoff points for mild, moderate, and severe pain.

This method, introduced by Serlin et al., has been widely applied. Cutoff points have been determined for various chronic pain conditions, such as cancer pain, diabetic neuropathy, osteoarthritis, low-back pain, phantom limb pain, neck pain, and musculoskeletal pain. In these studies, cutoff points for mild pain ranged from 2 to 5, while cutoff points for severe pain ranged from 6 to 8. The results of these studies suggest that the pain experience and pain-related functional impairment depends on the condition and the affected site. However, cutoff points for nondental orofacial pain have not been identified. Identifying cutoff points for mild, moderate, and severe nondental orofacial pain would aid clinicians and investigators in defining a measurable target range of adequate pain relief. The severity and impact of the different orofacial pains is large, especially if rare conditions, such as trigeminal neuralgia (TN) and the trigeminal autonomic cephalalgias, are included. The cutoff points could also be used to determine entry into clinical trials.

The aim of this study was to identify cutoff points between mild, moderate, and severe non dental orofacial pain, to assess if the cutoff points can be generally applied to all nondental orofacial pain conditions or if they are specific to each of the disorders, and to determine if the cutoff points discriminate between three intensity categories in several patient-related outcome measures (functional impairment, pain-related disability, depression, and anxiety).

Materials and methods

The study was reviewed and approved by the European Association of Oral Medicine board. All patients referred to the national Facial Pain Unit in London during a 6-week period in 2009 were asked to participate in the study. The Facial Pain Unit sees 700 new patients and 1,400 follow-up patients per year, and all patients have previously seen at least one primary care provider.

Criteria for referral to the unit are chronic pain, ie, over 3 months and exclusion of dental causes. Therefore, a 6-week period was assumed to provide a representative sample of non dental orofacial pain patients in terms of demographics and diagnosis.

The inclusion criteria were presence of nondental orofacial pain for more than 3 months, age over 18 years, and ability to understand questionnaires (one of the essential requirements for assessment in the clinic is the completion of several questionnaires that assess patients’ treatment expectations, sociodemographic data, pain intensity, pain-related interference, and pain-related disability). Theoretically, patients who did not understand the questionnaires would have been excluded from the study, but this did not occur, as the questionnaires were sent out ahead of the appointment and patients were encouraged to ask for help if they had difficulties completing them. Fifteen however did not complete all the questions, and so were excluded.

Demographic and clinical data (age, sex, duration of pain, and number of specialists seen before referral to the Facial Pain Unit) were registered. Intensity and pain-related functional impairment were assessed by the BPI. This uses an eleven-item NRS (0–10), where patients rate their worst, least, average, and current pain intensity, as well as interference with various aspects of everyday life (general activity, mood, walking, work, relationships with other people, sleep, and enjoyment in life). Pain-related disability was assessed by the Chronic Graded Pain Scale. This classifies patients into four disability categories (1, low intensity, low disability; 2, high intensity, low disability; 3, high disability, moderately limiting; and 4, high disability, severely limiting) based on interference with everyday activity and period of limited activity because of pain. The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depression. According to the HADS score, patients were classified as follows: 0–7, no depression/anxiety; 8–10, borderline depression/anxiety; and 11 and over, depression/anxiety.

Patients were classified into three subgroups according to their diagnosis: all types of TN, myogenic temporomandibular disorder (TMD) and persistent/chronic idiopathic facial pain (CIFP). TN was diagnosed according to the International Classification of Headache Disorders criteria. The diagnosis of TMD was made according to the following criteria: 1) pain and tenderness of the muscles of mastication of 3 months’ duration or longer and 2) no clinical and/or radiographic evidence of organic temporomandibular joint disorder. The third group was heterogeneous, and consisted of patients who did not fit into the previous two groups (patients with CIFP, burning mouth syndrome, and posttraumatic neuropathic pain). The diagnoses of these were made according to the International Classification of Headache Disorders criteria.
Statistical analysis

SPSS software (version 20 for Windows; IBM, USA) was used for data analysis. Depending on the distribution of the data, mean and standard deviation or median and range were used to summarize the data. For categorical variables, differences between groups were tested by the χ² test. For numerical variables, group differences were assessed by one-way analysis of variance (ANOVA), followed by post hoc Bonferroni test or the Krukal–Wallis test followed by Mann–Whitney U tests, with P-values adjusted for multiple testing if the assumptions of the ANOVA were not satisfied.

Determination of cutoff points was performed as described by Serlin et al.³ Average pain intensity was classified into nine schemes with different cutoff points of mild, moderate and severe pain: 1, scheme 35 (mild 1–3, moderate 4–5, severe 6–10); 2, scheme 36 (mild 1–3, moderate 4–6, severe 7–10); 3, scheme 37 (mild 1–3, moderate 4–7, severe 8–10); 4, scheme 38 (mild 1–3, moderate 4–8, severe 9–10); 5, scheme 46 (mild 1–4, moderate 5–6, severe 7–10); 6, scheme 47 (mild 1–4, moderate 5–7, severe 8–10); 7, scheme 48 (mild 1–4, moderate 5–8, severe 9–10); 8, scheme 57 (mild 1–5, moderate 6–7, severe 8–10); and 9, scheme 58 (mild 1–5, moderate 6–8, severe 9–10). Nine multivariate one-way ANOVAs were performed, with the intensity group (mild, moderate, and severe) as the independent variable and seven pain-interference domains from the BPI as the dependent variable. The scheme with the most significant intergroup differences, expressed by the smallest P-value determined from Wilks’ lambda, was considered to indicate the maximum difference between the groups, and thus provided the cutoffs between mild, moderate, and severe pain.

To assess if the determined cutoff points discriminated adequately between pain-intensity categories, patients were compared on various outcome measures using one-way ANOVAs, followed by Bonferroni post hoc comparisons where appropriate (for pain-related interference), or χ² tests (for pain-related disability, depression, and anxiety). In all analyses, P<0.01 was considered statistically significant. This significance level was chosen rather than the conventional 0.05 level to avoid spuriously significant results arising from multiple testing. Effect size was expressed by η² or ϕ-coefficient where appropriate.

Results

Demographic and clinical characteristics of the participants

A total of 112 patients had TMD, 85 patients had CIFP, and 48 patients had TN. The median age of the participants was 47 (range 18–84) years. The demographic and clinical data of the patients are shown in Table 1.

No significant difference in sex was observed between the three groups of patients. A significant difference in median age was observed between the groups: TN patients were significantly older than CIFP and TMD patients (P=0.002 and P<0.001, respectively). CIFP patients were on average significantly older than patients with TMD (P<0.001). Median duration of pain was significantly longer in TN patients compared to TMD and CIFP patients (P<0.001 and P=0.027, respectively). TN and CIFP patients visited significantly more pain specialists before referral to the Facial Pain Unit than TMD patients (P=0.004 and P<0.001, respectively). No significant difference in the proportion of patients with anxiety and depression was found between the three groups of participants.

The mean value of the average pain intensity was significantly higher in CIFP patients than in TMD patients (P=0.003). No significant differences in the mean values of average pain intensity were observed between TMD and TN patients or CIFP and TN patients (P=0.999 and P=0.186, respectively). No significant differences were observed in the mean worst, least, and current pain-intensity scores between three groups of participants (P=0.081, P=0.025, and P=0.097, respectively). No significant differences in pain-related interference were observed between the three groups of participants (P=0.058). No significant differences in pain-related disability were observed between the three groups of participants (P=0.206).

Determination of cutoff points

Cut-off points were determined as described in the Materials and methods section. The combination that showed the greatest intergroup differences for all patients was scheme 47 (mild 1–4, moderate 5–7, severe 8–10). The same combination provided the greatest intergroup differences in TMD and CIFP patients. Among the TN patients alone, the combination with the highest intergroup differences was scheme 48 (mild 1–4, moderate 5–8, severe 9–10) (Table 2). No significant difference in cutoff points between males and females was observed. (η² ranged from 0.35 – 0.41, indicating strong effect).

Assessment of cutoff points

As explained in the Materials and methods section, in order to assess if the optimal cutoff points discriminated between
Table I Demographic and clinical data of the patients

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>TMD</th>
<th>CIFP</th>
<th>TN</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>186</td>
<td>90</td>
<td>63</td>
<td>33</td>
<td>0.333</td>
</tr>
<tr>
<td>Male</td>
<td>59</td>
<td>22</td>
<td>22</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>245</td>
<td>112</td>
<td>85</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td><strong>Age, years, median (range)</strong></td>
<td>47 (12–84)</td>
<td>36.5 (12–77)</td>
<td>50 (23–84)</td>
<td>64 (20–81)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Duration of pain, months, median (range)</td>
<td>27 (6–468)</td>
<td>24 (6–180)</td>
<td>36 (6–360)</td>
<td>64 (6–468)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td><strong>Referred by, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GDP</td>
<td>71 (41%)</td>
<td>37 (52.1%)</td>
<td>27 (37.5%)</td>
<td>7 (23.3%)</td>
<td>0.051</td>
</tr>
<tr>
<td>GMP</td>
<td>43 (24.9%)</td>
<td>18 (25.4%)</td>
<td>15 (20.8%)</td>
<td>10 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Specialist</td>
<td>59 (34.1%)</td>
<td>16 (22.5%)</td>
<td>30 (41.7%)</td>
<td>13 (43.3%)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of specialists visited before the referral, median (range)</strong></td>
<td>2 (0–7)</td>
<td>1 (0–6)</td>
<td>2 (0–7)</td>
<td>2 (0–5)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td><strong>Depression, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>60 (52.2%)</td>
<td>41 (67.2%)</td>
<td>15 (57.7%)</td>
<td>19 (67.9%)</td>
<td>0.140</td>
</tr>
<tr>
<td>Borderline/mild depression</td>
<td>25 (21.7%)</td>
<td>12 (19.7%)</td>
<td>3 (11.5%)</td>
<td>7 (25%)</td>
<td></td>
</tr>
<tr>
<td>Severe depression</td>
<td>30 (26.1%)</td>
<td>8 (13.1%)</td>
<td>8 (30.8%)</td>
<td>2 (7.1%)</td>
<td></td>
</tr>
<tr>
<td><strong>Anxiety, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>75 (65.2%)</td>
<td>27 (44.3%)</td>
<td>16 (61.5%)</td>
<td>17 (60.7%)</td>
<td>0.493</td>
</tr>
<tr>
<td>Borderline/mild anxiety</td>
<td>22 (19.1%)</td>
<td>16 (26.2%)</td>
<td>4 (15.4%)</td>
<td>5 (17.9%)</td>
<td></td>
</tr>
<tr>
<td>Severe anxiety</td>
<td>18 (15.7%)</td>
<td>18 (29.5%)</td>
<td>6 (23.1%)</td>
<td>6 (21.4%)</td>
<td></td>
</tr>
<tr>
<td><strong>Pain intensity, mean ± SD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>4.9±2.9</td>
<td>4.3±2.7</td>
<td>5.7±2.8</td>
<td>5.2±3.2</td>
<td>0.004*</td>
</tr>
<tr>
<td>Worst</td>
<td>5.7±3.2</td>
<td>5.2±3.2</td>
<td>6.2±3.0</td>
<td>6.3±4.0</td>
<td>0.081</td>
</tr>
<tr>
<td>Least</td>
<td>3.5±3.1</td>
<td>3.2±2.9</td>
<td>4.2±3.1</td>
<td>3.8±3.6</td>
<td>0.025</td>
</tr>
<tr>
<td>Current</td>
<td>4.1±3.2</td>
<td>3.7±3.1</td>
<td>4.7±3.1</td>
<td>4.3±3.5</td>
<td>0.097</td>
</tr>
<tr>
<td>Pain-related interference, mean ± SD</td>
<td>3.7±2.9</td>
<td>3.3±2.8</td>
<td>4.3±3.0</td>
<td>3.8±3.3</td>
<td>0.055</td>
</tr>
<tr>
<td><strong>Pain-related disability, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>64 (28.1%)</td>
<td>38 (36.9%)</td>
<td>16 (21.3%)</td>
<td>10 (20%)</td>
<td>0.206</td>
</tr>
<tr>
<td>Grade 2</td>
<td>62 (27.2%)</td>
<td>28 (27.2%)</td>
<td>22 (29.3%)</td>
<td>12 (24%)</td>
<td></td>
</tr>
<tr>
<td>Grade 3</td>
<td>35 (15.4%)</td>
<td>14 (13.6%)</td>
<td>14 (18.7%)</td>
<td>7 (14%)</td>
<td></td>
</tr>
<tr>
<td>Grade 4</td>
<td>67 (29.3%)</td>
<td>23 (22.3%)</td>
<td>23 (30.7%)</td>
<td>21 (42%)</td>
<td></td>
</tr>
</tbody>
</table>

Notes: *P<0.01. Specialist—health care professional with dental or medical specialization; number of specialists visited before the referral, number of medical and/or dental specialists that patient saw before he/she was referred to the Facial Pain Unit; pain intensity (average, worst, least, right now), intensity subscales of the Brief Pain Inventory; pain-related interference, overall interference calculated from the interference subscales of the Brief Pain Inventory; pain-related disability determined by the Chronic Graded Pain Scale.

Abbreviations: TMD, temporomandibular disorder; CIFP, chronic idiopathic facial pain; TN, trigeminal neuralgia; SD, standard deviation; GDP, general dental practitioner; GMP, general medical practitioner.

the pain-intensity categories, the three intensity groups were compared on various outcome measures using univariate oneway ANOVAs, followed by Bonferroni post hoc comparisons where appropriate (pain-related interference), or χ² tests (pain-related disability, depression, and anxiety).

Pain interference in pain-intensity groups
In all patients, a significant difference in the means between mild-, moderate-, and severe-pain categories was found for all BPI interference scales, as well as for overall interference (Figure 1); η² ranged from 0.26 to 0.57, indicating a strong effect. In the subgroup of TMD patients, a significant difference between mild, moderate, and severe pain was found for all BPI interference scales, as well as for overall interference. A post hoc test did not reveal significant difference in interference with walking ability among patients with mild and moderate pain (P=0.286); η² ranged from 0.22 to 0.61, indicating a moderate-to-strong effect. In the subgroup of CIFP patients, a significant difference between mild, moderate, and severe pain was found for all BPI interference scales, as well as for overall interference. Post hoc tests did not reveal significant differences in inter-
### Table 2 Combination of cutoff points with associated Wilks' lambda statistics

<table>
<thead>
<tr>
<th></th>
<th>35</th>
<th>36</th>
<th>37</th>
<th>38</th>
<th>46</th>
<th>47</th>
<th>48</th>
<th>57</th>
<th>58</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild 1–3,</td>
<td>Mild 1–3,</td>
<td>Mild 1–3,</td>
<td>Mild 1–4,</td>
<td>Mild 1–4,</td>
<td>Mild 1–4,</td>
<td>Mild 1–5,</td>
<td>Mild 1–5,</td>
<td>Mild 1–5,</td>
</tr>
<tr>
<td></td>
<td>moderate &gt;3–5,</td>
<td>moderate &gt;3–6,</td>
<td>moderate &gt;3–7,</td>
<td>moderate &gt;4–6,</td>
<td>moderate &gt;4–7,</td>
<td>moderate &gt;4–8,</td>
<td>moderate &gt;5–7,</td>
<td>moderate &gt;5–8,</td>
<td>moderate &gt;5–8,</td>
</tr>
<tr>
<td></td>
<td>severe &gt;5–10</td>
<td>severe &gt;6–10</td>
<td>severe &gt;7–10</td>
<td>severe &gt;8–10</td>
<td>severe &gt;7–10</td>
<td>severe &gt;8–10</td>
<td>severe &gt;7–10</td>
<td>severe &gt;8–10</td>
<td>severe &gt;8–10</td>
</tr>
<tr>
<td>CIFP</td>
<td>6.097</td>
<td>5.557</td>
<td>5.667</td>
<td>5.113</td>
<td>5.985</td>
<td>6.276</td>
<td>6.004</td>
<td>5.678</td>
<td>5.781</td>
</tr>
<tr>
<td>TN</td>
<td>4.375</td>
<td>4.077</td>
<td>4.575</td>
<td>5.523</td>
<td>4.306</td>
<td>5.899</td>
<td>6.129</td>
<td>5.244</td>
<td>5.511</td>
</tr>
</tbody>
</table>

**Notes:** Numbers in bold represent different cutoff point combinations of mild, moderate, and severe pain. The scheme with the most significant intergroup difference, expressed by the smallest $P$-value determined from Wilks' lambda, indicates the maximum difference between the groups providing optimal cutoffs between mild, moderate, and severe pain (shaded cells).

**Abbreviations:** TMD, temporomandibular disorder; CIFP, chronic idiopathetic facial pain; TN, trigeminal neuralgia.

---

### Discussion

The results of this study indicate that in nondental orofacial pain conditions, the reduction in equal interval of pain intensity on an NRS will not produce the same level of reduction in functional impairment. This finding confirms the correlation between pain intensity and functional impairment as suggested by Serlin et al. Using the eleven-item grading the intensity of nondental facial pain (mild, moderate and severe pain) and TN subgroups ($P<0.001$) and $P<0.001$, respectively), $F$ values ranged from 0.3 to 0.56, indicating a strong effect.

A significant association was found between intensity of pain and anxiety in pain-intensity groups as in all treatments with moderate and severe pain ($P=0.016$; and $P=0.015$, respectively). Furthermore, in the TN subgroup, no significant differences in interference with walking ability and sleep were found between patients with mild and moderate pain ($P=0.366$ and $P=0.318$, respectively).

A significant association was found between intensity of pain (mild, moderate and severe pain) and depression in all patients. As in all three subgroups of patients ($P<0.001$, and $P<0.001$, respectively), $F$ values ranged from 0.66 to 0.73, indicating a moderate-to-strong effect. A significant association was observed between pain intensity and pain-related disability. This was observed in all patients, as well as in the overall grading the intensity of nondental facial pain, peripheral diabetic neuropathy, knee phantom limb pain, and fibromyalgia. No significant differences in interference with mood or enjoyment of life among patients with moderate and severe pain ($P=0.786$ and $P=0.270$, respectively).

No significant differences were found in interference with walking ability and sleep were significant differences in interference with walking ability and sleep were found between patients with mild and moderate pain ($P=0.366$ and $P=0.318$, respectively). Furthermore, in the TN subgroup, no significant differences in interference with walking ability and sleep were found between patients with mild and moderate pain ($P=0.366$ and $P=0.318$, respectively).
osteoarthritis, and cancer pain. 5–8 Chronic pain conditions like back pain, general pain, neck pain, and headache had different combinations of optimal cutoff points. 4,6,17 These findings indicate that the impact of chronic pain on daily activities does not depend solely on the pain intensity, but is also dependent on the nature of the condition.

Demographic factors, such as sex and age, did not affect the established cutoff points. It is known that chronic
Grading the intensity of nondental facial pain

orofacial pain conditions, such as TN, TMD, and CIFP, are more prevalent among women. Women tend to report higher pain intensity and duration of pain.\textsuperscript{18,19} However, no difference between men and women was found in any of the studies that determined cutoff points for mild, moderate, and severe pain in different chronic pain conditions.\textsuperscript{4–10} It seems that the impact of pain on everyday function diminishes sex-related differences in pain perception. There are no studies that compare pain intensity in different age-groups for CIFP and TN. The exception is TMD, where pain intensity appears to decrease with age of 60 years and over.\textsuperscript{20–22}

Even though anxiety and depression are often found in chronic pain, their relationship is not linear.\textsuperscript{23–25} Anxiety and depression depend not only on pain intensity but also on other factors. The figures below illustrate the anxiety and depression in the three pain-intensity groups.

Figure 3 Anxiety and depression in the three pain-intensity groups.

Abbreviations: TMD, temporomandibular disorder; CIFP, chronic idiopathic facial pain; TN, trigeminal neuralgia.
factors, such as pain acceptance, individual coping strategies, and other risk factors. A significant difference between the three pain-intensity groups was found only for TMD and TN patients. The difference was not statistically significant in the CIFP group, which could be due to heterogeneity of the group or the aforementioned mentioned pain acceptance and individual coping strategies. Anxiety and depression were used for the comparison of intensity groups in only two studies that used the same method for the identification of cutoff points in chronic pain. Paul et al did not find significant difference in either depression or anxiety between cancer patients classified as having mild, moderate, and severe pain. On the other hand, in a study of Hoffman et al, anxiety and depression subscales discriminated significantly between pain-intensity subgroups in patients with diabetic neuropathy. The difference between the studies could have been due to the use of different scales for the assessment of depression and anxiety: Paul et al used the shortened version of the Profile of Mood States, while Hoffmann et al used the HADS. In spite of the differences, it remains important to monitor patients’ psychological health, as chronic pain is a risk factor for the onset of anxiety and/or depressive disorders.

Cutoff points are not characteristic for an individual condition, but can be used in almost all nondental chronic orofacial pain conditions. The exception was TN patients, where the highest intergroup difference was obtained in scheme 48 (mild pain 1–4, moderate >4–8, severe >8–10). There can be several reasons for this. First of all, the group of TN patients was very small, and the statistical analysis could have been affected by the subtle changes in the number of patients in intensity-level subgroups. On the other hand, these results could reflect the character of TN. Despite high pain intensity, the pain in TN is episodic, and higher pain intensity and longer duration may be needed to result in a meaningful interference with daily activities. Furthermore, in the majority of TN patients, pain can be adequately controlled with medications that can have a positive impact on pain-related interference with daily activities. Having experienced very severe episodes of pain, patients with TN may be more discriminating about their pain severity, ie, they often distinguish between what they term “twinges” compared to “electric shocks”. Unlike TN, in TMD and CIFP the pain is more or less constant and often not successfully controlled with medications that can affect patients’ daily activities and quality of life. Furthermore, patients with TMD and CIFP are more likely to have other chronic pain and more psychosocial predisposing factors than TN patients, and so require a holistic treatment approach.

Only 17% of the TN patients in this cohort compared to 90% of patients in the TMD and CIFP subgroups had other chronic pain including headache. This might explain why lower pain intensity can result in higher disability/functional impairment.

Classification of mild, moderate, and severe pain as defined in this study is in line with patients’ definition of acceptable outcome. According to the studies of Thorne and Morley and Farrar et al on more than 2,000 patients with various chronic pain conditions, patients’ definition of “much improvement” implies reduction of 2–3 raw points or 30% on an NRS. In TMD patients, clinically important change was defined as an intensity visual analog scale score reduction of 19.5 mm and percentage change of 37.9% from baseline. Percentage change showed higher sensitivity, since raw visual analog scale score reduction was significantly affected by the baseline pain levels. Furthermore, the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) recommends reporting on the percentages of patients achieving ≥30% reduction in the NRS, since this reduction appears to reflect at least moderate clinically important difference. Reduction of ≥50%, on the other hand, reflects substantial improvement and should also be reported. This is especially relevant in TN, where unlike other types of nondental orofacial pain, nearly 100% pain reduction can be achieved; if not by medication, then by surgery.

This study has several limitations that need to be addressed. According to Hirschfeld and Zernikow, the statistical method for determination of cutoff points applied in this study does not take into account the variability of the sample. The authors state that the differences between the groups were as a result of a chance variation rather than true differences in pain-related interference. Bootstraping was performed, the rank ordering of the cut-off points was not affected, and the combination of 47 and 48 was still identified as the most appropriate for TMD, CIFP, and TN. The cutoff points could not represent the optimal relationship between pain intensity and functional interference in every individual patient, but for the majority of nondental orofacial pain patients, these measures are probably valid. Furthermore, one of the pain characteristics not assessed in the BPI that could be of importance is interference with eating. An extended BPI, called BPI facial, which includes seven additional oral/facial parameters, has recently been validated in patients with TN. However, no data are yet available on its
validity in other facial pain conditions. Therefore, we decided to use a validated instrument, as was used in all similar studies. Another limitation of this study is the small number of TN patients. Further studies with larger numbers of patients are therefore required.

In spite of the study limitations, we believe that the cutoff points determined in this study discriminate pain-intensity categories reasonably well and provide significant difference in most of the outcome measures used. These cutoff points would help clinicians and researchers to define more precisely satisfactory levels of pain relief in nondental orofacial pain patients. They would be of use in clinical trials and for providers of pain services when assessing pain-related outcome measures.

Acknowledgments

We are grateful to Aviva Petrie and David Boniface, who advised on the statistical analysis. VB undertook this work as part of his grant from the European Association of Oral Medicine. JMZ undertook this work at UCL/UCLHT, who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centre funding.

Author contributions

Both authors collected the data and contributed to the manuscript equally. Both authors discussed the results and commented on the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References


